6-氟-2-巯基苯并噻唑 | 80087-71-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 6-氟-2-巯基苯并噻唑
• 中文别名: 6-氟-2-疏基苯并噻唑
• 英文名称: 6-fluoro-2-mercaptobenzothiazole
• 英文别名: 6-fluorobenzo[d]thiazole-2-thiol；6-fluoro-3H-1,3-benzothiazole-2-thione
• CAS: 80087-71-4
• 化学式: C₇H₄FNS₂
• mdl: MFCD00665747
• 分子量: 185.246
• InChiKey: XDZVUKOOUHIRKY-UHFFFAOYSA-N

物化性质

• 熔点：
  225-227 °C(Solv: chloroform (67-66-3); ligroine (8032-32-4))
• 沸点：
  304.4±44.0 °C(Predicted)
• 密度：
  1.55±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  69.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934200090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温下，应密封保存，并确保环境干燥。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Fluoro-2-mercaptobenzothiazole
Synonyms: 6-Fluorobenzo[d]thiazole-2-thiol

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Fluoro-2-mercaptobenzothiazole
CAS number: 80087-71-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H4FNS2
Molecular weight: 185.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-氟-2-巯基苯并噻唑 在 三乙烯二胺 、 磺酰氯 作用下， 以 水 、 二甲基亚砜 为溶剂， 反应 14.0h， 生成 6-氟-1,3-苯并噻唑-2-甲腈
  参考文献：
  名称：

  快速获得广泛的 6'-取代萤火虫荧光素类似物揭示了令人惊讶的发射器和抑制剂

  摘要：

  发光萤火虫萤光素类似物在 6'-位含有供电子基团，但已知 6'-取代的范围仍然很窄。开发了一种获得广泛 6'-取代的荧光素类似物的两步路线，以填补这一空白，并能够对 6'-功能进行更广泛的研究。这种化学反应可以直接获得“笼状”酰胺和明亮的氮杂环丁烷类似物，但也揭示了硫醚抑制剂和出人意料的发光芳胺衍生物。

  DOI：

  10.1021/acs.orglett.7b02806
• 作为产物：
  描述：

  二硫化碳 、 2-碘-4-氟苯胺 在 四甲基溴化铵 、 caesium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 14.0h， 以86%的产率得到6-氟-2-巯基苯并噻唑
  参考文献：
  名称：

  3H-苯并噻唑-2-硫酮及其衍生物的更清洁、更环保的合成

  摘要：

  本通讯报道了一种更清洁、更环保的 3H-苯并噻唑-2-硫酮合成方法。在该方法中，各种邻碘苯胺衍生物在 Cs2CO3 和四甲基溴化铵 (TMAB) 的存在下与二硫化碳反应，以更高的收率得到 3H-苯并噻唑-2-硫酮及其衍生物。图形概要

  DOI：

  10.1080/17415993.2020.1803321

文献信息

• [EN] PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS<br/>[FR] COMPOSES DE PYRAZINE COMME INHIBITEURS DE PHOSPHODIESTERASE 10
  申请人：AMGEN INC

  公开号：WO2010057121A1

  公开（公告）日：2010-05-20

  Pyrazine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

  吡嗪化合物、含有它们的组合物以及制备这些化合物的方法。还提供了通过抑制PDE10治疗可治疗的疾病或病症的方法，例如肥胖、非胰岛素依赖型糖尿病、精神分裂症、双相情感障碍、强迫症等。
• General Entry into <i>o</i> -,<i>o′</i> -Heteroatom-Linked <i>N</i> -(Hetero)aryl-Imidazole Motifs by Gold-Catalysed Formal [3+2]-Dipolar Cycloaddition
  作者：Miguel Garzón、Elsa M. Arce、Raju Jannapu Reddy、Paul W. Davies

  DOI：10.1002/adsc.201700249

  日期：2017.6.6

  general redox‐neutral approach into the o‐,o′‐heteroatom‐linked N‐(hetero)aryl‐imidazole family of heteroaromatics has been developed. New types of heteroatom substituted carbimidoyl nitrenoids are efficiently realised from robust, bench‐stable N‐(heteroaryl)‐pyridinium‐N‐aminides by formal gold‐catalysed [3+2]‐dipolar cycloadditions across ynamides. Broad structural variety and functional group tolerance

  已开发出一种将杂芳烃的邻，邻杂原子连接的N-（杂）芳基-咪唑家族的氧化还原中性方法。新型的杂原子取代的碳酰亚胺基亚硝基化合物可以通过稳定的，稳定的N-（杂芳基）-吡啶鎓-N-胺类化合物，通过正式的金催化的[3 + 2]-偶极环加成酰胺类有效地实现。广泛的结构多样性和官能团耐受性允许快速进入各种功能化的支架，如制备8个不同的杂芳族核心所示。
• Heterocyclic compounds
  申请人：Zeneca Limited

  公开号：US05451594A1

  公开（公告）日：1995-09-19

  The invention provides compounds of formula (I) having nematicidal, insecticidal, acaricidal and fungicidal properties, compositions comprising them and processes and intermediates for their preparation: ##STR1## wherein: X is oxygen or sulphur; n is 0, 1 or 2; R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are as described in the specification.

  该发明提供具有杀线虫、杀虫、杀螨和杀菌性质的公式(I)化合物，包含它们的组合物以及它们的制备过程和中间体：##STR1## 其中：X是氧或硫；n是0、1或2；R.sup.1、R.sup.2、R.sup.3和R.sup.4如说明书中所描述。
• Substituted benzothiazoles, benzimidazoles, and benzoxazoles
  申请人：The Upjohn Company

  公开号：US04873346A1

  公开（公告）日：1989-10-10

  The present invention provides certain novel substituted benzothiazoles, benzimidazoles and benzoxazoles which are useful as inhibitors of leukotriene biosynthesis and/or as inhibitors of the action of lipoxygenase and/or as inhibitors of mucus secretion in mammalian metabolism. They are thus employed wherever it is medically necessary or desirable to inhibit these systems.

  本发明提供了一些新颖的取代苯并噻唑、苯并咪唑和苯并噁唑化合物，它们可用作白三烯生物合成的抑制剂和/或脂氧化酶活性的抑制剂和/或哺乳动物代谢中粘液分泌的抑制剂。因此，在医学上需要或希望抑制这些系统的地方可以使用它们。
• NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS
  申请人：Stein Philip D.

  公开号：US20090011994A1

  公开（公告）日：2009-01-08

  The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R 1 , R 2 , R 3 , R 8 , and R 9 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

  本申请提供了根据公式I提供的化合物，包括所有立体异构体、溶剂合物、前药和药学上可接受的形式， 其中 R 1 ，R 2 ，R 3 ，R 8 和R 9 在此定义。 此外，本申请提供了含有至少一种根据公式I的化合物和可选至少一种额外治疗剂的药物组合物。最后，本申请提供了治疗患有MCHR-1调节性疾病或紊乱的患者的方法，例如肥胖症、糖尿病、抑郁症或焦虑症，通过给予根据公式I的化��物的治疗有效剂量。